Novo Nordisk A/S: Federal Circuit Court rules on patent litigation involving Prandin(R) (repaglinide)

BAGSVAERD, DENMARK--(Marketwired - Jun 18, 2013) - Today, the U.S. Court of Appeals for the Federal Circuit partially affirmed a 2011 District Court decision, with a 2-1 ruling that a claim in a Novo Nordisk patent related to the use of repaglinide in combination with metformin for the treatment of type 2 diabetes was invalid. This decision favors approval and launch of a generic repaglinide product.

The Federal Circuit also reversed, with a unanimous 3-0 ruling, the District Court decision that Novo Nordisk had committed inequitable conduct during the time the company attempted to acquire the patent.

Novo Nordisk continues to believe in the validity of the patent and is reviewing the ruling. Novo Nordisk expects to provide an update on the case in connection with the announcement of the financial results for the first six months of 2013 on 8 August 2013.

Novo Nordisk markets repaglinide under the trade name Prandin® and a fixed-dose repaglinide/metformin tablet under the trade name PrandiMet® in the US. In 2012, sales of Prandin® and PrandiMet® in the US amounted to 1.2 billion Danish kroner (approximately 200 million USD).

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Company Announcement No 45: http://hugin.info/2013/R/1710375/567079.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novo Nordisk A/S via Thomson Reuters ONE

[HUG#1710375]